Millions of Americans enrolled in Medicare stand-alone prescription drug plans face a critical financial turning point as the open enrollment window progresses toward its December 7 deadline. According to a new comprehensive analysis released by KFF, the average monthly premium for Medicare Part D coverage in stand-alone prescription drug plans, commonly referred to as PDPs, is projected to climb to $51 in 2027. This marks a staggering 50% increase from the average monthly premium of $34 recorded in 2026, assuming that current enrollees do not proactively switch to lower-cost plans before the enrollment period closes.
The new research highlights a stark and widening financial gap between stand-alone prescription drug plans and Medicare Advantage plans that incorporate drug coverage, known as MA-PDs. While the projected average monthly premium of $51 for stand-alone PDPs represents a substantial burden for consumers, the equivalent drug coverage integrated within Medicare Advantage plans is projected to average a mere $9 per month next year. This means that the average stand-alone PDP premium is slated to be more than five times higher than the drug coverage premium offered through Medicare Advantage plans. Furthermore, the trajectory of these costs points in drastically different directions: the estimated $17 jump in the average monthly stand-alone PDP premium contrasts sharply with an expected increase of less than $2 in monthly premiums for drug coverage bundled into MA-PD plans.
"With some plans increasing premiums substantially, the stakes are higher this year for people with Medicare stand-alone drug coverage if they sit on the sidelines during open enrollment," said Juliette Cubanski, a vice president and director of the Program on Medicare Policy at KFF. Cubanski emphasized that while financial relief is technically available for those willing to navigate the marketplace, consumers cannot afford to remain passive. "There are relatively low-premium PDP options, but people facing large premium increases need to take action if they want to avoid paying significantly more," she added.
The urgency of the current open enrollment period is underscored by the reality facing millions of beneficiaries who currently pay nothing for their coverage. The vast majority of PDP enrollees who do not receive extra financial subsidies specifically designed for low-income participants will see their monthly bills rise in 2027 if they maintain their current selections. This group includes more than 4 million enrollees who are currently signed up for stand-alone prescription drug plans that charge a zero-dollar premium. The financial shock for these individuals will be unavoidable if they fail to switch, largely because the KFF analysis reveals that there will be no zero-premium stand-alone PDP options available anywhere in the marketplace for 2027.
The national landscape for stand-alone prescription drug plans illustrates a massive variance in pricing structure across different providers. Average monthly premiums for the eight major national PDPs are projected to range dramatically, spanning from approximately $6 to more than $204 in 2027. At the lower end of the pricing spectrum, Centene’s Wellcare Value Script Rx stands out as the most affordable national PDP option, carrying an average projected monthly premium of $6.50 for 2027, representing a modest increase from its $5.80 average in 2026. Conversely, the highest-premium national PDP identified in the analysis is United’s AARP Medicare Rx Preferred plan, which features a projected average monthly premium of $204.50, up steeply from $126.00 in 2026. This enormous spread underscores why policy experts and consumer advocates are repeatedly stressing the importance of thorough plan comparison before the December 7 deadline.
Beyond monthly premiums, the KFF analysis reveals that enrollees across virtually all standard and Medicare Advantage prescription drug plans will face significantly higher out-of-pocket hurdles in the form of deductibles. For 2027, the vast majority of Part D enrollees will be required to meet a deductible amounting to several hundred dollars before their plan begins sharing the cost of medications. Specifically, 85% of MA-PD enrollees—up from 80% in 2026—and an overwhelming 99.8% of PDP enrollees—up from 96% in 2026—will be subject to a deductible if they keep their current plans unchanged.
Federal regulatory guidelines permit Part D plans to charge a maximum deductible of up to $700 in 2027, which is an increase from the $615 ceiling enforced in 2026. While individual plans retain the discretion to establish lower deductible thresholds, the baseline costs are climbing across the board. On average, the standard Part D deductible in 2027 will reach $643 for standalone PDP enrollees, marking a notable jump from the $540 average recorded in 2026. For beneficiaries enrolled in Medicare Advantage prescription drug plans, the average deductible will rise to $489, up from $360 in the previous year.
Compounding these financial pressures, the KFF findings indicate that most Part D enrollees will increasingly encounter coinsurance requirements rather than traditional fixed copayments. This shift applies to both preferred brand-name medications and non-preferred drugs. Unlike predictable copayments, which charge a flat dollar amount per prescription regardless of the drug’s list price, coinsurance requires the consumer to pay a fixed percentage of the drug’s total cost. This structural shift can introduce substantial volatility and less predictable out-of-pocket expenses for beneficiaries managing chronic conditions or relying on expensive specialty medications throughout the year.
With the open enrollment window closing on December 7, the findings serve as a stark reminder of the financial consequences tied to inaction in the Medicare marketplace. As average monthly premiums climb to $51 for stand-alone plans, zero-dollar premium options vanish entirely, and deductibles expand closer to the federal maximum, millions of older adults and individuals with disabilities face mounting pressure to actively review their coverage options, compare competing plans, and transition to more affordable alternatives to safeguard their household budgets against steep cost increases in the coming year.
